BridgeBio Oncology Therapeutics, Inc. Research and Development Expense
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Research and Development Expense of $49.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $49.23M, a 79.40% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $39.80M, a 92.89% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $38.07M, a 94.85% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $35.05M, a 95.94% increase year-over-year.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $49.23M 10-Q · filed 2026-08-11 | $89.03M 10-Q · filed 2026-08-11 | $127.10M derived: sum of 3 quarters · filed 2026-08-11 | $162.15M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $39.80M 10-Q · filed 2026-05-12 | $77.88M derived: sum of 2 quarters · filed 2026-05-12 | $112.93M derived: sum of 3 quarters · filed 2026-05-12 | $140.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $38.07M 8-K · filed 2026-03-05 | $73.13M derived: sum of 2 quarters · filed 2026-03-05 | $100.56M derived: sum of 3 quarters · filed 2026-08-11 | $121.20M POS AM · filed 2026-04-30 |
| 2025-09-30 | $35.05M 10-Q · filed 2025-11-12 | $62.49M derived: sum of 2 quarters · filed 2026-08-11 | $83.13M 10-Q · filed 2025-11-12 | $102.67M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $27.44M 10-Q · filed 2026-08-11 | $48.07M 10-Q · filed 2026-08-11 | $67.61M derived: sum of 3 quarters · filed 2026-08-11 | $85.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $20.64M 10-Q · filed 2026-05-12 | $40.17M derived: sum of 2 quarters · filed 2026-05-12 | $58.06M derived: sum of 3 quarters · filed 2026-05-12 | |
| 2024-12-31 | $19.54M 8-K · filed 2026-03-05 | $37.43M derived: sum of 2 quarters · filed 2026-03-05 | $73.11M POS AM · filed 2026-04-30 | |
| 2024-09-30 | $17.89M 10-Q · filed 2025-11-12 | $53.57M 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |